Minnie  Kuo net worth and biography

Minnie Kuo Biography and Net Worth

Ms. Kuo serves as our Chief Operating Officer. She joined Pliant in September 2023.

Ms. Kuo is an experienced biotechnology and pharmaceutical executive and brings more than 20 years of multinational clinical development experience across various therapeutic areas including respiratory, oncology, neurodegenerative and inflammatory. Ms. Kuo joined Pliant from holding roles of increasing responsibilities at Vir Biotechnology, most recently serving as Senior Vice President of Translational and Clinical Development Operations. In this role, Ms. Kuo served as the operational officer to the Chief Medical Officer, overseeing business operations, clinical operations, and organizational planning across the entire clinical portfolio. Prior to Vir, Ms. Kuo held senior clinical operations roles at Nektar Therapeutics and Gilead Sciences. At Gilead, she oversaw the strategic direction of multiple compounds and indications within the company’s inflammation and hepatic portfolios. Earlier in her career, Ms. Kuo held global project management and clinical study management roles at the clinical research organization ICON and at Roche/ Genentech.

Ms. Kuo received her B.A. in biochemistry and healthcare from the University of California, San Diego, and a M.S in organizational development from the University of San Francisco.

What is Minnie Kuo's net worth?

The estimated net worth of Minnie Kuo is at least $41.96 thousand as of January 20th, 2026. Ms. Kuo owns 37,806 shares of Pliant Therapeutics stock worth more than $41,965 as of September 22nd. This net worth estimate does not reflect any other investments that Ms. Kuo may own. Learn More about Minnie Kuo's net worth.

How do I contact Minnie Kuo?

The corporate mailing address for Ms. Kuo and other Pliant Therapeutics executives is 331 Oyster Point Boulevard, South San Francisco, CA, 94080. Pliant Therapeutics can also be reached via phone at 650-481-6770 and via email at [email protected]. Learn More on Minnie Kuo's contact information.

Has Minnie Kuo been buying or selling shares of Pliant Therapeutics?

Minnie Kuo has not been actively trading shares of Pliant Therapeutics during the last quarter. Most recently, Minnie Kuo sold 6,917 shares of the business's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $1.28, for a transaction totalling $8,853.76. Following the completion of the sale, the chief operating officer now directly owns 37,806 shares of the company's stock, valued at $48,391.68. Learn More on Minnie Kuo's trading history.

Who are Pliant Therapeutics' active insiders?

Pliant Therapeutics' insider roster includes Bernard Coulie (CEO), Minnie Kuo (COO), and Eric Lefebvre (Insider). Learn More on Pliant Therapeutics' active insiders.

Are insiders buying or selling shares of Pliant Therapeutics?

In the last year, insiders at the sold shares 2 times. They sold a total of 96,292 shares worth more than $123,253.76. The most recent insider tranaction occured on January, 20th when CEO Bernard Coulie sold 89,375 shares worth more than $114,400.00. Insiders at Pliant Therapeutics own 8.7% of the company. Learn More about insider trades at Pliant Therapeutics.

Information on this page was last updated on 1/20/2026.

Minnie Kuo Insider Trading History at Pliant Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/20/2026Sell6,917$1.28$8,853.7637,806View SEC Filing Icon  
See Full Table

Minnie Kuo Buying and Selling Activity at Pliant Therapeutics

This chart shows Minnie Kuo's buying and selling at Pliant Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pliant Therapeutics Company Overview

Pliant Therapeutics logo
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $1.12
Low: $1.12
High: $1.12

50 Day Range

MA: $1.11
Low: $1.03
High: $1.19

2 Week Range

Now: $1.12
Low: $1.02
High: $1.95

Volume

267 shs

Average Volume

589,944 shs

Market Capitalization

$69.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27